Abstract
In our cohort, FGFR3 mutations were detected in 31.1% of bladder tumors and are associated with lower stage and grade. Concerning TP53, 62 mutations were found in tumors from 44 cases (48.88%) and are associated with advanced forms. The combined analysis of FGFR3 and TP53 mutations in our cohort showed an independent distribution. In addition, we have reported that FGFR3 mutations spectrum depends on the intensity of tobacco use (pack years: PY). Finally, we have found that the FGFR3wt/TP53mut genotype, which was associated with advanced bladder tumors; was overrepresented in light smokers (PY < 40) compared to nonsmoker patients (p =.01).
MeSH terms
-
Aged
-
Black People / genetics*
-
Carcinoma / ethnology
-
Carcinoma / etiology*
-
Carcinoma / genetics
-
Carcinoma / pathology
-
Exons
-
Female
-
Gene Expression Regulation, Neoplastic
-
Genetic Predisposition to Disease
-
Humans
-
Male
-
Middle Aged
-
Mutation*
-
Neoplasm Invasiveness
-
Neoplasm Staging
-
Odds Ratio
-
Phenotype
-
Receptor, Fibroblast Growth Factor, Type 3 / genetics*
-
Risk Assessment
-
Risk Factors
-
Smoking / adverse effects*
-
Smoking / ethnology
-
Tumor Suppressor Protein p53 / genetics*
-
Tunisia / epidemiology
-
Urinary Bladder Neoplasms / ethnology
-
Urinary Bladder Neoplasms / etiology*
-
Urinary Bladder Neoplasms / genetics
-
Urinary Bladder Neoplasms / pathology
-
Urothelium / pathology
Substances
-
TP53 protein, human
-
Tumor Suppressor Protein p53
-
FGFR3 protein, human
-
Receptor, Fibroblast Growth Factor, Type 3